IP Library Granted Patent US 9,345,703
Granted Patent B2
US 9,345,703 · App. 14/345,273 · Granted May 24, 2016

Kappa opioid receptor effectors and uses thereof

Inventors: Jeffrey Aube (Lawrence, KS); Laura Bohn (Jupiter, FL); Thomas Edward Prisinzano (Lawrence, KS); Frank John Schoenen (Lawrence, KS); Kevin John Frankowski (Lawrence, KS)
Assignees: University of Kansas; The Scripps Research Institute
A61K31/4985A61K31/4196A61K31/444A61K31/4439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,703
App. No.
14/345,273
Granted
May 24, 2016
Kind
B2
Abstract

The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.

Claims (23)

1. A pharmaceutical composition comprising an effective amount of a kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier, wherein the kappa opioid receptor effector is an antagonist of Formula I or agonist of Formula II:

wherein

X, Y and Z are independently selected from H,H; O; S or NH;

R 1 is H, a halogen group or a substituted or unsubstituted lower alkyl or alkoxy group, wherein the substituents on the lower alkyl or alkoxy group are selected from the group consisting of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, oxo, —CF 3 , and —CN;

R 2 is a substituent on one or more ring atoms and is for each ring atom independently H, a halogen group, or a substituted or unsubstituted lower alkyl or alkoxy group, wherein the substituted lower alkyl or alkoxy group comprises one or more substituents selected from the group of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, oxo, —CF 3 , and —CN;

X′ is hydrogen or Br;

one Z′ is N and the other Z′ is C, CH or N;

n is 0 or 1;

R 3 is naphthyl; cycloalkyl; —C≡CH; —C═CH 2 ; phenyl with two or more substituents independently selected from the group of lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, iodo, nitro, nitroso, carboxyl, sulhydryl, —CF 3 , and —CN; or phenyl substituted with a trifluoromethyl group and a halogen or alkyl group; and

R 4 is aryl, substituted aryl, heteroaryl, substituted heteroaryl or cycloalkyl, wherein the heteroaryl or substituted heteroaryl is a 5- or 6-membered aromatic ring with at least one heteroatom selected from the group of N, O or S; and substituted aryl or substituted heteroaryl comprises one or more substituents selected from the group of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, —CF 3 , and —CN.

2. The pharmaceutical composition of claim 1 , further comprising a kappa opioid receptor agonist.

3. The pharmaceutical composition of claim 1 , wherein R 4 is 2-furyl, 2-thiophene or 3-pyridyl.

4. A method for treating an ethanol use disorder, an anxiety disorder, a depressive illness, schizophrenia, a post-traumatic stress disorder, or mania associated with bipolar disorder, acute mania, or chronic mania comprising administering to a subject having an ethanol use disorder, an anxiety disorder, a depressive illness, schizophrenia, a post-traumatic stress disorder, or mania associated with bipolar disorder, acute mania, or chronic mania a kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, wherein the kappa opioid receptor effector is an antagonist of Formula I or agonist of Formula II:

wherein

X, Y and Z are independently selected from H,H; O; S or NH;

R 1 is H, a halogen group or a substituted or unsubstituted lower alkyl or alkoxy group, wherein the substituents on the lower alkyl or alkoxy group are selected from the group consisting of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, oxo, —CF 3 , and —CN;

R 2 is a substituent on one or more ring atoms and is for each ring atom independently H, a halogen group, or a substituted or unsubstituted lower alkyl or alkoxy group, wherein the substituted lower alkyl or alkoxy group comprises one or more substituents selected from the group of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, oxo, —CF 3 , and —CN;

X′ is hydrogen or Br;

each Z′ is independently C, CH or N;

n is 0 or 1;

R 3 is phenyl, substituted phenyl, naphthyl, cycloalkyl, —C≡CH or —C═CH 2 , wherein the substituted phenyl comprises one or more substituents independently selected from the group of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, iodo, nitro, nitroso, carboxyl, sulhydryl, —CF 3 , and —CN; and

R 4 is aryl, substituted aryl, heteroaryl, substituted heteroaryl or cycloalkyl, wherein the heteroaryl or substituted heteroaryl is a 5- or 6-membered aromatic ring with at least one heteroatom selected from the group of N, O or S; and substituted aryl or substituted heteroaryl comprises one or more substituents selected from the group of halogen, lower alkyl, lower alkoxy, alkenyl, hydroxyl, amino, nitro, nitroso, carboxyl, sulhydryl, —CF 3 , and —CN.

5. The method of claim 4 , wherein R 4 is 2-furyl, 2-thiophene or 3-pyridyl.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2023
From: THE SCRIPPS RESEARCH INSTITUTE
To: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Reel/Frame 063741/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2023
From: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 063741/0383 →
CONFIRMATORY LICENSE Recorded May 4, 2015
From: UNIVERSITY OF KANSAS LAWRENCE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035570/0998 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2014
From: AUBE, JEFFREY; PRISINZANO, THOMAS EDWARD; SCHOENEN, FRANK JOHN; FRANKOWSKI, KEVIN JOHN
To: UNIVERSITY OF KANSAS
Reel/Frame 032653/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2014
From: BOHN, LAURA
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 032653/0823 →
Continuity (2)
Provisional Application 61534938 · Sep 15, 2011
Related Publication 20140371227A1 · Dec 18, 2014